Navigation Links
AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
Date:11/12/2008

All amounts are in U.S. dollars

QUEBEC CITY, Nov. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has signed a definitive agreement to sell to Cowen Healthcare Royalty Partners, L.P. ("CHRP") its rights to royalties on future sales of Cetrotide(R) covered by its license agreement with Merck Serono. The license agreement between AEterna Zentaris and Merck Serono was signed in 2000 and granted Merck Serono exclusive rights to market, distribute and sell Cetrotide(R) worldwide, with the exception of Japan, in the field of in vitro fertilization. On closing, AEterna Zentaris will receive $52.5 million from CHRP. In addition, contingent on 2010 net sales of Cetrotide(R) reaching a specified level, AEterna Zentaris would receive an additional payment of $2.5 million from CHRP.

Under the terms of the agreement, if cetrorelix, which is currently in Phase 3 clinical trials for the treatment of benign prostatic hyperplasia, is approved for sale by European regulatory authorities in an indication other than in vitro fertilization, AEterna Zentaris has agreed to make a one-time cash payment to CHRP in an amount ranging from $5 million up to a maximum of $15 million. The amount which would be due to CHRP will be higher the earlier the product receives European regulatory approval.

"We are very pleased with this transaction which is in line with our strategy of generating non-dilutive financing through non-core asset monetization," said Juergen Engel, Ph.D., President and Chief Executive Officer of AEterna Zentaris. "We now expect to end the year 2008 with approximately $50 million in cash, providing us
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... ... in Personalized Medicine, recently hosted their 2015 bi-annual Pain Management Medical Advisory Board ... met with Proove Biosciences’ executive Research and Development team to discuss new clinical ...
(Date:7/6/2015)... June 29, 2015 ... the addition of the "Biotechnology for the ... Biotechnology for the Non-Biotechnologist, ideal for non-Scientists and ... techniques and potential of biotechnology. Ideal ... basic theory, principles, techniques, and potential of biotechnology ...
(Date:7/5/2015)... ... , ... For many years, metal-on-quartz filters were the industry standard for the ... Varian Cary 4000-7000, a Perkin Elmer 800-1100 or a Shimadzu 3600-3700, these filters would ... for their SRM-2031 series going back for many years. Unfortunately, these standards remained unusable ...
(Date:7/3/2015)... ... ... global failure analysis market is expected to reach $7,147.0 million by 2020, at a ... at the highest CAGR of 8.46%; its growth is expected to be driven by ... for root cause analysis of failure. The market based on the geographic regions has ...
Breaking Biology Technology:Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 2Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 3FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 2FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5
... SOUTH SAN FRANCISCO, Calif., Jan. 12 Sunesis Pharmaceuticals, ... clinical update on voreloxin, its novel investigational drug candidate ... myeloid leukemia (AML) and ovarian cancer. The clinical ... Annual JP Morgan Healthcare Conference in San Francisco. "2008 ...
... Calif., Jan. 12 MAP,Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical programs, Unit Dose Budesonide (UDB) for children,with ... For UDB, all,patients have completed the 12 week ... for MAP0004, the company currently expects to complete,enrollment in ...
... Calif., Jan. 12 Anacor Pharmaceuticals today,announced that it ... million from its collaboration partner, GlaxoSmithKline. Anacor may,receive ... to clinical development and commercial sales. , ... we have made as a result of,the alliance we ...
Cached Biology Technology:Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 2Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 3Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 4Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 5Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 6MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 2MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 3Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate 2
(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
(Date:7/2/2015)... 2, 2015 Fingerprint Cards has received ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... be used by smartphone manufacturers in Asia ... the communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Latin America Biomedical Sensors Market Report 2015-2020 2
... passage of the Endangered Species Act in 1973, over 1,300 ... its territories. In the forthcoming issue of Ecology Letters, Male ... status trends and show that the length of time species ... conservation are key variables in explaining trends. , Overall, about ...
... analyze DNA from giant, extinct lemurs, according to a Yale ... the National Academy of Sciences. , Radiocarbon dating of the ... that each of the individuals analyzed died well over 1,000 ... professor in the Department of Ecology and Evolutionary Biology. , ...
... Novel use of genetic testing methods helped public health ... outbreaks of foodborne hepatitis A virus in 2003 related ... detailed analysis published in the October 15 issue of ... The authors of the study, Joseph J. Amon, PhD, ...
Cached Biology News:Ancient DNA confirms single origin of Malagasy primates 2Disrupting Cocaine-memories To Battle Addiction 2